EUCTR2010-019525-34-FR进行中（未招募）1 期
GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMA - ROSiA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,021
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Histologically confirmed and documented high risk International Federation of Gynecologic Oncology (FIGO) Stage I–IIa (only if grade 3 / poorly differentiated) or Stage IIb–IV (any grade) epithelial ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma or
- •Histologically confirmed and documented clear cell carcinoma regardless of the FIGO stage (clear cell carcinoma is defined as either = 50% clear cell elements present or reported as clear cell carcinoma by the local pathologist).
- •Histologically confirmed and documented carcinosarcoma.
- •Patients with recurrent ovarian cancer that have been previously treated with surgery alone for their early stage disease are eligible.
- •Patients should have already undergone surgical debulking, by a surgeon experienced in the management of ovarian cancer, with the aim of maximal surgical cytoreduction according to the GCIG Conference Consensus Statement. There must be no planned surgical debulking prior to disease progression. Patients with stage III and IV disease in whom initial surgical debulking was not appropriate will still be eligible providing
- •- the patient has a histological diagnosis and
- •- debulking surgery prior to disease progression is not foreseen
- •Eligible for carboplatin (or cisplatin) and paclitaxel chemotherapy treatment in accordance with local standards of care following cytoreductive surgery. Patients who have received neo-adjuvant chemotherapy may be included. In such patients bevacizumab is started in addition to the post-surgical chemotherapy cycles.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with:
- •non-epithelial ovarian cancer
- •ovarian tumors with low malignant potential (i.e. borderline tumors)
- •synchronous primary endometrial carcinoma, unless all of the following criteria related to the endometrial carcinoma are met:
- •ostage =Ia
- •ono more than superficial myometrial invasion
- •ono lymphovascular invasion
- •onot poorly differentiated (grade 3 or papillary serous or clear cell carcinoma).
- •Previous systemic therapy for ovarian cancer (i.e. chemo-, immuno-, hormonal, monoclonal antibody or tyrosine kinase inhibitor therapy). Prior neo-adjuvant chemotherapy is allowed.
- •Radiotherapy within 28 days of Day 1, Cycle 1. Patients may be given palliative radiotherapy to peripheral sites (e.g. bone metastasis) during this 28 day period but they must have recovered from any acute effects. Prior radiotherapy to any portion of the abdominal cavity or pelvis is not permitted.
- •Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to first dose of bevacizumab.
- •anticipation of the need for major surgery during the course of the study treatment (planned elective surgery).
- •Inadequate bone marrow function / liver function / renal function
研究者
相似试验
进行中（未招募）
不适用
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerEPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMAMedDRA version: 17.0Level: LLTClassification code 10052204Term: Ovarian carcinosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019525-34-LTF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
不适用
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerEUCTR2010-019525-34-ATF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
不适用
GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMAEstudio global para evaluar la adición de bevacizumab a carboplatino y paclitaxel como tratamiento en primera línea del cáncer epitelial de ovario, carcinoma de trompas de Falopio o carcinoma peritoneal primario. - ROSiAEUCTR2010-019525-34-ESF. Hoffmann-La Roche Ltd1,000
进行中（未招募）
不适用
A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian CancerEPITHELIAL OVARIAN CANCER FALLOPIAN TUBE CARCINOMA PRIMARY PERITONEAL CARCINOMAMedDRA version: 16.1Level: LLTClassification code 10052204Term: Ovarian carcinosarcomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019525-34-HUF. Hoffmann-La Roche Ltd1,000
招募中
3 期
GLOBAL STUDY TO ASSESS THE ADDITION OF BEVACIZUMAB TO CARBOPLATIN AND PACLITAXEL AS FRONT-LINE TREATMENT OF EPITHELIAL OVARIAN CANCER, FALLOPIAN TUBE CARCINOMA OR PRIMARY PERITONEAL CARCINOMAovariancancerovariancarcinoma1003859410033283NL-OMON39830Roche Nederland B.V.40